Evaluation of a classical unani pharmacopeial formulation safoof-e-muhazzil in hyperlipidemia: A randomized, standard controlled clinical study

Abstract

Aim of the Study:The aim of the following study is to evaluate the efficacy and tolerability of a compound Unani formulation in hyperlipidemia on clinical and biochemical parameters.Materials and Methods:A total of 90 patients with total cholesterol level of 220 mg/dl and above were included. In Group ‘A’ thirty patients with total cholesterol 243.5 ± 5.294 mg/dl received Unani formulation safoof-e-muhazzil (SM) in its classical powder form 5 g twice daily orally, in Group ‘B’ thirty patients with total cholesterol 234 ± 3.822 mg/dl received the SM but in compressed tablet form in the same dosage and in Group ‘C’ 30 patients with total cholesterol 242.7 ± 5.563 mg/dl received atorvastatin 10 mg as a standard control. Follow-up was carried out on second, fourth and 6th week and patients were evaluated on clinical as well as biochemical parameters.Results:Group A before treatment had mean total cholesterol of 243.5 ± 5.294 mg/dl which decreased significantly after treatment to 225.6 ± 5.953 mg/dl (P < 0.001) with a percentage change of 7.35%. Group B had mean total cholesterol of 234 ± 3.822 mg/dl which was significantly reduced to 212.67 ± 3.94 mg/dl (P < 0.001) post-treatment with a percentage change of 9.11%. Control Group C having mean total cholesterol of 242.7 ± 5.563 mg/dl before treatment was significantly decreased to 178.73 ± 4.669 mg/dl (P < 0.001) post-treatment with a percentage change of 26.3%. Group A had significant relief 20.72% (P < 0.001) in fatigue, 16.09% (P > 0.5) relief in palpitation and 26.17% (P < 0.001) relief in dyspnea post-treatment. Group B fatigue decreased significantly by 18.14% (P < 0.01), palpitation by 22.91% (P < 0.01) and dyspnea by 20.46% (P < 0.01). In Group C a non-significant increase of 2.2% was observed in fatigue post-treatment, palpitation decreased by 10.22% non-significantly and dyspnea decreased significantly by 17.64% (P < 0.001). Results indicate that the test drug safely and effectively ameliorates the clinical condition of patients with hyperlipidemia while decreasing cholesterol level as well.

Untitled

“…SMC and SMT managed weight three to four times better than control on all four parameters. Four studies established the efficacy of Safoof e Muhazzil in obesity 16,24,25,26 as is also evident from our study. However, this is the first study that compares its efficacy with a changed dosage form.…”

“…Safoof e Muhazzil is a classical pharmacopeial Unani drug of choice for obesity 13 . The phytoconstituents of the drug are anti-inflammatory, anti-obesity, antioxidant, diuretic, vaso-relaxant, antihypertensive and lipolytic 7, 14,15,16 . But the dosage form is a bitter-tasting powder that is less palatable; hence its patient compliance is poor; therefore, an acute need was felt for a change in its dosage form.…”

A Review on Management of Meniere’s Disease with Unani Medicine

“…The following are the etiological factors: exposure to cold air, swimming or diving, prodding the external auditory canal, noise pollution, and untreated chronic systemic disease. According to Unani physicians the treatment is based on lifestyle modification, warming up the body, strengthening the brain and the nervous system, enhancing the digestive system, modifying the condition of defecation, as well as the removal of waste materials and accumulated abnormal humors from the body, especially from the head (Jahangir et al, 2014).…”

Dyslipidemia and its concept in Unani medicine: A review

“…They can also balance the Akhlat (Humors), such as Badyan (Foeniculm vulgare) [37] , Bikh Ajmod (Apium graveolens) [38] , Gudmar Booti (Gymnema sylvestre) [39] , Halela (Terminalia chebula) [40,41] , Lehsun (Allium sativum) [42,43] , Kaloonji (Nigella Sativa) [42] , Luk Maghsul (Laccifer lacca) [43] , Methi (Trigonella foenum-graecum) [44] , Sandrus (Trachelobium hornemanianum), Saad kofi (Cyperus rotundus), Soya (Anethum sowa) [45] , Sumbuluttib (Valeriana officinalis), Tukhme Karafs (Apium graveolens) [46] and Tukhme Suddab (Ruta graveolens) [47] Kasni (Cichorium intybus) [47] , Maku (Solanum nigrum) [48] , Afsanteen (Artemisia absinthium) [49] , Muquil (Commiphora mukul) [50] , Chhal Arjun (Terminalia arjuna) [51] , Badranjboya (Mellisa officinalis) [52] , Abresham (Bombyx mori) [53] , which have been reported as having antihyperlipidemic activity. Various Unani formulation have been used by physicians, based on their clinical experiences, to manage dyslipidemia and Farbahi such as Safoof Kalonji [54] , Habbe Sundarus [35] , Qurs Luk [55] , Itriphal Sagheer [56] , Majoon Sheer Alvi Khan [57] and Safoof Muhazzil [58,59] . [60] are the same as those stated by Sina [11] , Rushd [11] , and Nafis [16] (deranged cold temperament).…”